Valion Bio, Inc.
VBIO
$1.10
-$0.01-0.90%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -9.75% | -34.44% | -28.56% | -1.69% | -3.21% |
| Total Depreciation and Amortization | -- | -100.00% | 0.00% | -99.63% | 27,200.00% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -18.83% | 228.98% | 76.00% | -82.88% | 678.67% |
| Change in Net Operating Assets | -138.10% | 128.77% | -114.26% | 168.72% | -1,332.69% |
| Cash from Operations | -14.58% | -9.25% | -105.51% | 34.87% | 2.99% |
| Capital Expenditure | -150.00% | -233.33% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | 100.00% | 96.77% | -- | -- |
| Cash from Investing | -1,390.00% | 50.00% | 96.20% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -100.00% | -77.52% | 1,650.46% | -90.22% | 7,333.33% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | 216.31% | 541.54% | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -366.67% | 168.70% | -385.19% | -142.86% | 156.25% |
| Cash from Financing | 172.26% | 80.86% | 2,780.49% | -93.04% | 1,314.43% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 305.78% | 340.00% | 138.63% | -612.83% | 87.57% |